References
- Gertz MA, Reeder CB, Kyle RA, Ansell SM. Stem cell transplant for Waldenstrom macroglobulinemia: an underutilized technique. Bone Marrow Transplant. 2011 Aug 29. [Epub ahead of print]
- Gertz MA. Waldenstrom macroglobulinemia: 2011 update on diagnosis, risk stratification, and management. Am J Hematol. 2011;86:411–6.
- Dimopoulos MA, Gertz MA, Kastritis E, Garcia-Sanz R, Kimby EK, Leblond V, et al.. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom’s Macroglobulinemia. J Clin Oncol. 2009;27:120–6.
- Treon SP. How I treat Waldenstrom macroglobulinemia. Blood. 2009;114:2375–85.
- Issa GC, Leblebjian H, Roccaro AM, Ghobrial IM. New insights into the pathogenesis and treatment of Waldenstrom macroglobulinemia. Curr Opin Hematol. 2011;18:260–5.
- Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, et al.. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc. 2010;85:824–33.
- Kastritis E, Terpos E, Dimopoulos MA. Emerging drugs for Waldenstrom's macroglobulinemia. Expert Opin Emerg Drugs. 2011;16:45–57.
- Dimopoulos MA, Chen C, Kastritis E, Gavriatopoulou M, Treon SP. Bortezomib as a treatment option in patients with Waldenstrom macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2010;10:110–7.
- Baehring JM, Hochberg EP, Raje N, Ulrickson M, Hochberg FH. Neurological manifestations of Waldenstrom macroglobulinemia. Nat Clin Pract Neurol. 2008;4:547–56.